Optimizing the Use of Novel Therapies for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) — September 18, 2026, Morgantown, WV

A CME/MOC-Accredited Interactive Grand Rounds Series

Date
Friday, September 18, 2026

Program Schedule — Eastern Time
7:30 AM – 8:00 AM — Registration and Breakfast
8:00 AM – 9:00 AM — Educational Program

Location
West Virginia University Cancer Institute
64 Medical Center Dr
Morgantown WV, 26506

Meeting Room
Fukushima Auditorium (Room 1901)

Faculty

Craig A Portell

University of Virginia, Charlottesville, Virginia

Professor of Medicine, Section Head — Hematologic Malignancies, Medical Director of Lymphoma/CLL/Myeloma Clinical Research Team, Division of Hematology/Oncology

Registration

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large b-cell lymphoma (DLBCL).

I am a:(Required)

Clinician / healthcare professional

Other / industry professional

Name(Required)

First Last

Email(Required)

Address(Required)

City State / Province / Region Country

Degree(Required)

Specialty(Required)

If you are a clinician, which of the following best describes your practice setting?(Required)

National Provider Identifier (NPI) Number

These activities are supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pfizer Inc.